AMINO AMSA-Indonesia EAMSC 2017 | Page 52

In order to better analyze the trend, the fold increase in GMTs from baseline to post-dose three were calculated for all 4 antigens in all studies for both test and control groups. This data can be seen in Table 3 and Figure 6 below:
Table 3: Fold Increase in GMT of each serotype from Baseline to the end of Third Dose
Dayan, et al( 2013)
HSS, et al( 2013)
Lanata, et al( 2012)
Sabchareon, et al( 2012)
Villar, et al( 2013)
Leo, et al( 2-11)( 2013)
Leo, et al( 12-17)( 2013)
DENV- 1( Test)
6.45
9.87
10.29
3.41
4.31
10.62
4.40
DENV- 1
( Control)
1.68
1.02
1.67
0.90
1.29
1.12
1.16
DENV-2( Test)
8.12
11.32
12.36
5.46
5.25
17.26
6.54
DENV-2
( Control)
1.93
0.88
1.19
1.19
1.33
1.14
1.11
DENV- 3( Test)
9.05
12.37
11.59
12.86
6.99
21.79
10.44
DENV- 3
( Control)
1.48
1.03
1.66
1.70
1.36
1.10
1.19
DENV-4( Test)
28.80
11.49
22.66
5.52
7.42
18.44
13.58
DENV-4
( Control)
1.91
0.89
1.87
0.84
1.07
1.34
1.27
35
30
25
20
15
10
5
0
DENV- 1( Test)
DENV- 1( Control)
DENV-2( Test)
DENV-2( Control)
DENV- 3( Test)
DENV- 3( Control)
DENV-4( Test)
DENV-4( Control)
Dayan, et al HSS, et al Lanata, et al Sabchareon, et al( 2012) Villar, et al Leo, et al( 2-11) Leo, et al( 12-17)
Figure 6: Fold Increase in Geometric Mean Titres of each serotype from Baseline to the end of Third Dose